What Granza Bio users actually want

Three sources establish that attack particles are positioned as a versatile platform applicable to cancers, autoimmunity, and infections—autonomous killing entities with broad therapeutic promise. This breadth is both a strength and a complexity risk. Product managers and engineering leads evaluating the platform need to see concrete, contextualized use cases to understand how the technology maps to their specific therapeutic area. Without this, the platform reads as theoretical rather than actionable.

The attack particle platform claims applicability across multiple disease contexts—cancer, autoimmunity, infections—and investor backing confirms stakeholders see commercial potential. But this breadth introduces execution complexity that the available evidence doesn't address. For product managers and founders evaluating the platform, the critical question is not whether the technology works in theory, but whether the team can deliver across multiple therapeutic areas simultaneously without diluting focus or missing milestones.

The current cookies policy reserves the right to update unilaterally with notification only via website posting—no explicit opt-in mechanism exists. This is standard practice across many web properties, but in a regulated biotech context where users are product managers, founders, and engineering leads making compliance-sensitive decisions, it creates a trust gap. These stakeholders need to know immediately when data handling practices change, not discover it passively on a website visit.

The cookies policy directs users to third-party privacy policies rather than Granza Bio taking ownership of how external analytics and advertising partners handle data. This delegation is legally safe but strategically weak—it signals that the company views data governance as someone else's problem. For product managers and founders evaluating the platform, this raises a red flag: if Granza Bio won't own third-party data handling, what happens when a partner has a breach or compliance failure.

The privacy policy acknowledges that no internet data transmission or electronic storage is completely secure—a standard disclaimer that nonetheless highlights endemic risk. For users in a regulated biotech environment, this acknowledgment without accompanying detail on security controls creates an evidence gap. Product managers and engineering leads need to see what mitigations are in place before they can assess whether the residual risk is acceptable for their use case.